Immune Effector Cell (IEC) Therapy: Infection Prophylaxis, Late Complications, and Survivorship

ONLINE



Date & Location
Monday, March 10, 2025, 12:00 AM - Thursday, March 9, 2028, 11:59 PM

Target Audience
Specialties - Adolescent Medicine, Advanced Heart Failure and Transplant Cardiology, Anesthesiology, Anesthesiology Critical Care Medicine, Blood Banking/Transfusion Medicine, Cardiovascular Disease, Clinical Neurophysiology, Critical Care Medicine, Dermatology, Dermatopathology, Diagnostic Radiology, Emergency Medical Services, Emergency Medicine, Family Medicine, Geriatric Medicine, Geriatric Psychiatry, Gynecologic Oncology, Hematopathology, Infectious Disease, Internal Medicine, Internal Medicine-Critical Care Medicine, Interventional Cardiology, Medical Oncology, Nephrology, Neurocritical Care, Neurological Surgery, Neurology, Neuropathology, Neuroradiology, Ophthalmology, Pathology, Pediatric Cardiology, Pediatric Critical Care Medicine, Pediatric Emergency Medicine, Pediatric Hematology-Oncology, Pediatric Infectious Diseases, Pediatric Neurology, Pediatric Transplant Hepatology, Pediatrics, Psychiatry, Pulmonary Disease, Radiology, Rheumatology
Professions - Nurse - APRN, Nurse - RN, Pharmacist, Pharmacy Technician, Physician (MD or DO), Physician Associate, Student or Trainee

Credits
AMA PRA Category 1 Credits™ (0.50 hours), AAPA Category 1 CME (0.50 hours), ABIM MOC Part 2 (0.50 hours), ACPE Contact Hour(s) (0.50 hours), ANCC - Nursing Contact Hour(s) (0.50 hours), Non-Physician Attendance (0.50 hours), Pharmacotherapeutics (0.50 hours)

Overview
This activity equips healthcare professionals with the latest updates and evidence-based approaches for managing infections and complications in patients undergoing immune effector cell (IEC) therapies, including CAR T-cell therapy. Emphasizing updates to MD Anderson Cancer Center’s algorithms for CAR T-cell management, the session provides current guidance on infection prophylaxis, monitoring, and survivorship care for IEC-treated patients.

Objectives
At the conclusion of this activity, learners will be able to:

  1. Identify appropriate infection prophylaxis and duration for immune effector cell (IEC) therapies.
  2. Demonstrate the latest protocols on CAR T therapy, including optimal lines of therapy, unique toxicities, complication management, antimicrobial prophylaxis, and survivorship.
  3. Outline appropriate monitoring for IEC-related infections.
  4. Discuss late complications that long-term survivors of IEC therapies may experience.

Accreditation

In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designations
The University of Texas MD Anderson Cancer Center designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Texas MD Anderson Cancer Center designates this enduring material will award 0.50 Nursing Contact Hour(s) which includes APRN 0.50 Pharmacotherapeutics credit(s).

The University of Texas MD Anderson Cancer Center has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. Approval is valid until March 9, 2028. PAs should only claim credit commensurate with the extent of their participation.

The University of Texas MD Anderson Cancer Center designates this knowledge-based activity for 0.50 hours under UAN JA0004118-0000-25-004-H06-P and UAN JA0004118-0000-25-004-H06-T. Credits will be provided to NABP CPE Monitor within 60 days after the activity completion. Learners must provide their NABP e-profile ID and Date of Birth in their MyCE Profile for credits to be reported to CPE Monitor.

American Board of Internal Medicine
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.


Additional Information

View the accessibility policy for The University of Texas MD Anderson Cancer Center.